-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Or8t5Gi+bgVy8mv++PBpWuW1Q5Suhxxc9leXgDpKLghpXHeMMQBBCwTQnQAYUx9m iKkmW+l9r4FALQKbYIBCkQ== 0000950134-04-017163.txt : 20041112 0000950134-04-017163.hdr.sgml : 20041111 20041112060555 ACCESSION NUMBER: 0000950134-04-017163 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20041112 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20041112 DATE AS OF CHANGE: 20041112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS INC CENTRAL INDEX KEY: 0001159036 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 880488686 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32335 FILM NUMBER: 041134805 BUSINESS ADDRESS: STREET 1: 11588 SORRENTO VALLEY ROAD STREET 2: SUITE 17 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 794-8889 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC DATE OF NAME CHANGE: 20010912 8-K 1 a03281e8vk.htm FORM 8-K Halozyme Therapeutics, Inc.
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

November 12, 2004

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)
         
Nevada   000-49616   88-0488686
  		 
  		 
 
(State or other jurisdiction
of incorporation) 		  (Commission
File Number) 		  (IRS Employer
Identification No.)
         
11588 Sorrento Valley Road, Suite 17, San Diego, California
   92121
 		  
 
(Address of principal executive offices)
   (Zip Code)

Registrant’s telephone number, including area code: (858) 794-8889

     
Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

TABLE OF CONTENTS

Item 8.01 Other Events.
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
EXHIBIT 99.1

Table of Contents

Item 8.01 Other Events.

     On November 10, 2004 Halozyme Therapeutics, Inc. (the “Company”) announced that it sent notices of redemption to warrant holders covering approximately 2,023,700 shares of its common stock. For 30 days following the notice, those warrant holders may exercise their warrants for $1.75 per share. If all affected warrants are exercised, the company will receive gross proceeds of approximately $3.5 million. After 30 days, the Company may purchase any of the affected warrants that are not exercised for $0.01 per share. The press release announcing this development is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

     (c) Exhibits

Exhibit
      Description
  99.1   Press Release issued by the Company on November 10, 2004.

 

Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  Halozyme Therapeutics, Inc.
 		  
November 12, 2004  By:   /s/ David A. Ramsay    
    David A. Ramsay   
    Secretary and Chief Financial Officer   
 

 

EX-99.1 2 a03281exv99w1.txt EXHIBIT 99.1 Exhibit 99.1 PRESS RELEASE Source: Halozyme Therapeutics, Inc. HALOZYME THERAPEUTICS CALLS FIRST TRANCHE OF WARRANTS FROM JANUARY 2004 FINANCING Wednesday November 10, 8:02 am ET SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Amex: HTI - News), a development stage biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that it has sent notices of redemption to warrant holders covering approximately 2,023,700 shares of its common stock. For 30 days following the notice, those warrant holders may exercise their warrants for $1.75 per share. If all affected warrants are exercised, the company would receive gross proceeds of approximately $3.5 million. After 30 days, Halozyme may purchase any of the affected warrants that are not exercised for $0.01 per share. Halozyme's offer and sale of the shares issuable upon exercise of these warrants have not been registered under the Securities Act of 1933 or any state securities law. Shares issuable upon exercise of these warrants may not be sold in the United States unless they are registered or an exemption from registration is available. In that regard, the Company noted that the shares issuable upon exercise of the warrants (including the warrants called for redemption) have been registered with the Securities and Exchange Commission. You may obtain copies of the prospectus contained in that registration statement from: David A. Ramsay Vice President -- Chief Financial Officer Halozyme Therapeutics, Inc. 11588 Sorrento Valley Road, Suite 17 San Diego, CA 92121 This notice shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any State in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state. About Halozyme Therapeutics, Inc. Halozyme Therapeutics, Inc. is a development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility (CUMULASE(TM)), ophthalmology (ENHANZE SC(TM)), and oncology (CHEMOPHASE(TM)) communities. The company's portfolio of products in development is based on intellectual property covering the family of human enzymes known as hyaluronidases. The first recombinant human hyaluronidase (rHuPH20) is being developed by Halozyme as a medical device (CUMULASE(TM)), drug enhancement agent (ENHANZE SC(TM)), and therapeutic biologic (CHEMOPHASE(TM)). Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the gross proceeds the Company would receive if all the affected warrants were exercised) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-KSB, 10-QSB and other filings with the Securities and Exchange Commission. -----END PRIVACY-ENHANCED MESSAGE-----